INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.14
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.45

05 Dec
2025

-0.020

OPEN

$2.47

-0.81%

HIGH

$2.51

302,175

LOW

$2.44

TARGET
$3.567 45.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 1.5 13.0 xxx
DPS (cps) xxx 6.5 8.7 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx 12.1% 34.4% xxx
PE Ratio xxx N/A 18.8 xxx
Dividend Yield xxx N/A 3.6% xxx
Div Pay Ratio(%) xxx 427.6% 67.0% xxx

Dividend yield today if purchased 3 years ago: 2.38%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.65

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx1.5
DPS All xxxxxxxxxxxxxxx6.5
Sales/Revenue xxxxxxxxxxxxxxx627.2 M
Book Value Per Share xxxxxxxxxxxxxxx186.2
Net Operating Cash Flow xxxxxxxxxxxxxxx73.8 M
Net Profit Margin xxxxxxxxxxxxxxx0.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx0.94 %
Return on Invested Capital xxxxxxxxxxxxxxx0.49 %
Return on Assets xxxxxxxxxxxxxxx0.43 %
Return on Equity xxxxxxxxxxxxxxx0.94 %
Return on Total Capital xxxxxxxxxxxxxxx5.90 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx20 M
Long Term Debt xxxxxxxxxxxxxxx565 M
Total Debt xxxxxxxxxxxxxxx585 M
Goodwill - Gross xxxxxxxxxxxxxxx802 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx52 M
Price To Book Value xxxxxxxxxxxxxxx1.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx59.8 M
Capex % of Sales xxxxxxxxxxxxxxx9.53 %
Cost of Goods Sold xxxxxxxxxxxxxxx489 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx82 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

04/11/2025

1

Buy

$3.30

34.69%

Integral Diagnostics delivered a strong start to FY26, assesses Ord Minnett, with first quarter like-for-like Australian revenue up 8.3%, driven by MRI deregulation tailwinds.

The analysts feel a higher-margin mix and Capitol Health synergies will support management's FY26 earnings (EBITDA) margin target of around 21%, up 90bps year-on-year.

The broker highlights accelerating MRI volumes, the ramp-up of new greenfield clinics, and scale benefits as key drivers of margin expansion through 2H26. Operating leverage and sector valuation support are expected to sustain earnings momentum.

Ord Minnett retains a Buy rating and $3.30 target.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 8.90 cents and EPS of 12.60 cents.
Ord Minnett forecasts a full year FY27 dividend of 10.60 cents and EPS of 15.10 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

29/09/2025

1

Buy

$3.20

30.61%

Management at Integral Diagnostics hosted a clinic tour at Imaging at Sydney's Olympic Park, which Canaccord Genuity describes as one of the leading musculoskeletal diagnostic imaging sites in Australia.

The broker points out the facility’s specialised focus, extended hours, and strong referrer relationships drive high utilisation and margin potential.

The third MRI (added in July 2025) is already lifting scan volumes to around 120-130 per day, with further upside possible during peak sporting periods, note the analysts.

Revenues of around $26m and earnings (EBITDA) of $13m in FY25 are forecast by Canaccord to rise to $30-31m and $16m, respectively, in FY26.

The broker sees scope for margin expansion from Olympic Park, further IDXt (the teleradiology arm) deployment, and acquisition synergies.

Canaccord maintains a Buy rating. The target slips to $3.20 from $3.40. 

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 7.80 cents and EPS of 10.80 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 8.50 cents and EPS of 12.20 cents.
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia